Personalized Therapies and Best Clinical Practices for Lung Cancer 2018
WebcastOVERVIEW
Personalized Therapies and Best Clinical Practices for Lung Cancer is organized by Biomedical Learning Institute (BMLI) and will be held from Jan 01, 2018 - Jan 01, 2019. This CME Conference has been approved for a maximum of 8.25 AMA PRA Category 1 Credits.
Course Overview:
This is an activity on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.
The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.
Target Audience:
This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to these CME/CE activities for personalized therapies and best clinical practices.
Learning Objectives :
• Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
• Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
• Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
• Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
Additional details will be posted as soon as they are available.
Course Overview:
This is an activity on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.
The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.
Target Audience:
This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to these CME/CE activities for personalized therapies and best clinical practices.
Learning Objectives :
• Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
• Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
• Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
• Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links